Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 16/04/21 | Issuer sale | Director | 80,000 | 0.1718% | ||
| 16/04/21 | Issuer sale | Director | 72,500 | 0.1557% | ||
| 16/04/21 | Issuer sale | Director | 80,000 | 0.1718% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| +0.69% | +1.73% | +64.62% | +119.89% | 55.35B | |
| +1.58% | +14.12% | +72.87% | +85.18% | 51.92B | |
| +0.38% | +0.06% | -14.98% | -15.60% | 22.76B | |
| +2.27% | +7.69% | +4.37% | +433.32% | 22.64B | |
| -0.18% | +7.48% | +32.16% | -14.07% | 17.36B | |
| -1.54% | +3.67% | +28.28% | -34.72% | 16.1B | |
| +3.02% | +12.74% | +143.33% | +308.04% | 13.96B | |
| +2.72% | +6.91% | +27.41% | +182.12% | 13.38B | |
| +1.31% | +6.52% | +28.62% | - | 12.27B | |
| Average | +1.04% | +5.82% | +42.96% | +133.02% | 25.08B | |
| Weighted average by Cap. | +1.10% | +6.54% | +48.06% | +123.90% |
Employees
51
